SCHEMBL9492399

SCHEMBL9492399

C=C(C)CN1C(=O)C(C)S/C1=N/N=C1/SC(O[Si](C(C)C)(C(C)C)C(C)C)C(=O)N1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9492404 1.00 — —
SCHEMBL9493763 0.85 — —
SCHEMBL9493766 0.85 — —
SCHEMBL9493692 0.84 — —
SCHEMBL9495179 0.83 — —
SCHEMBL9495175 0.83 — —
SCHEMBL9494743 0.83 — —
SCHEMBL9494748 0.83 — —
SCHEMBL10876986 0.81 ALDH1A1 (0.33) —
SCHEMBL9494827 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0494047-A1 Use of carbazones for the treatment of rheumatoid diseases CIBA-GEIGY AG (CH) 1992-07-08 — — EP claimed
US-5177091-A Rheumatic disorders CIBA-GEIGY CORPORATION (US) 1993-01-05 — — US disclosed
EP-0494047-A1 Use of carbazones for the treatment of rheumatoid diseases CIBA-GEIGY AG (CH) 1992-07-08 — — EP disclosed
Send feedback